ACCOMPLISHMENTS

• Board certified by the American Board of Toxicology and the Regulatory Affairs Professionals Society
• Recipient of a Merck Frosst Special Achievement Award for contribution to the discovery of PIFELTRO™, a non-nucleoside reverse transcriptase inhibitor, marketed for the treatment of HIV-1
• Contributed to the discovery, nonclinical development and successful regulatory filing of several small molecule investigational new drugs and marketing authorizations in jurisdictions worldwide (USA, Europe, UK, Canada, Australia and Japan)
• Currently holds an adjunct appointment in the Department of Biomedical and Molecular Sciences at Queen’s University in Kingston, Ontario, Canada
• Councillor on the Board of Directors of the Society of Toxicology of Canada (2009-2012)
• Councillor on the executive committee of the Drug Discovery Specialty Section of the Society of Toxicology (2014-2016)
• President of the Roundtable of Toxicology Consultants (2022)
• Sole author of the book chapter on Toxicokinetics in Hayes’ Principles and Methods in Toxicology, 7th Edition
• Invited Speaker in the Toxicology for Pharmaceutical and Regulatory Scientists course (2024-present) and in the Advanced Comprehensive Toxicology course (2022-present) offered by the American College of Toxicology
• Invited Speaker in the Drug Discovery in Neuroscience Seminar Series, Harvard Medical School/Boston’s Children’s Hospital (2024)
• Elected as Councillor, American College of Toxicology (2025)